Inclusion Criteria:

          -  Histologically proven diagnosis of recurrent and/or metastatic salivary duct cancer;
             adenocarcinoma, NOS; and AR expression in at least 70% of nuclei of neoplastic cells
             based on central review

          -  Sufficient tissue must be available either historically or a biopsy must be done as a
             part of this study and sent to central review for patients enrolled in both cohorts

          -  Presence of at least one uni-dimensional measurable lesion by CT-scan or MRI according
             to RECIST criteria version 1.1 (target lesion).

          -  Patients older than 18 years old;

          -  Performance Status ECOG 0-1;

          -  Adequate bone marrow function:

          -  WBC ≥ 3.5/10exp9L

          -  absolute neutrophil count ≥ 1,5x10exp9/L

          -  hemoglobin > 9 g/dL

          -  platelet count ≥ 100x10exp9/L

          -  Adequate liver function:

          -  AST < 2.5 times upper limit of normal

          -  ALT < 2.5 times upper limit of normal

          -  bilirubin < 1.5 times upper limit of normal

          -  the concomitant evidence of AST < 2.5 times upper limit of normal, ALT < 2.5 times
             upper limit of normal and bilirubin > 1.5 times upper limit of normal is not allowed

          -  Adequate renal function:

          -  serum creatinine level (≤ 1.3 mg/dL)

          -  calculated creatinine clearance ≥ 60 mL/min based on the standard Cockcroft and Gault
             formula

          -  Adequate cardiac function as demonstrated by a clinically normal 12 lead ECG;
             additionally for patients who will receive Cisplatin and Doxorubicin adequate cardiac
             function should be demonstrated by a left ventricular ejection fraction (LVEF) ≥ 50%
             (within 2 weeks prior to treatment start)

        Exclusion Criteria:

          -  Actively bleeding tumor if the patient is intended to be treated with carboplatin

          -  Patients with bone disease or brain disease as the sole disease site; brain metastases
             are allowed in case of systemic disease, but must have been treated at least 4 weeks
             before enrollment and must be stable after that;

          -  recent history of congestive heart failure, unstable angina within the past 3 months,
             cardiac arrhythmia, myocardial infarction, congenital long QTc prolongation, stroke,
             TIA within the past 6 months;

          -  previous cardiac toxicity induced by another anthracycline or previous exposure to
             maximum cumulative dose of another anthracycline if the patient is intended to be
             treated with doxorubicin

          -  history of allergic reactions attributed to compounds of similar chemical or
             biological composition to cis/carboplatin, paclitaxel, doxorubicin, bicalutamide or
             triptorelin;

          -  concomitant medications with terfenadine, astemizole, cisaprid

          -  use of phenytoin

          -  Patients who received vaccine for yellow fever

          -  active second malignancy during the last five years except non melanomatous skin
             cancer or carcinoma in situ of the cervix;

          -  positive serum pregnancy test within 1 week prior to the first dose of study treatment
             for Women of child bearing potential (WOCBP);

          -  no adequate birth control measures, as defined by the investigator, during the study
             treatment period and for at least 6 months after the last study treatment for patients
             of childbearing / reproductive potential.

          -  psychological, familiar, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule; those conditions should be
             discussed with the patient before registration in the trial;

          -  written informed consent not given according to ICH/GCP, and national/local
             regulations, before patient registration

          -  participation in another interventional clinical trial in the preceding 4 weeks prior
             to randomization

          -  for cohort A patients: previous chemotherapy for recurrent/metastatic disease
             (previous chemotherapy given concomitantly with RT in the past is allowed, including
             cisplatin but it should be completed at least 6 months before enrollment).